Kenneth A Lock Net Worth & Insider Trades
Kenneth A Lock - Chief Commercial Officer, Arcutis Biotherapeutics, Inc
What is Kenneth A Lock's Net Worth?
The current estimated net worth of Arcutis Biotherapeutics, Inc's Chief Commercial Officer, Kenneth A Lock, is estimated to be about $194.97K . Kenneth A Lock owns about 63,429 units of Arcutis Biotherapeutics, Inc common stock. In the last 3 years at Arcutis Biotherapeutics, Inc, Kenneth A Lock has sold an estimated value of $116.22K worth.
What is Kenneth A Lock's Past Insider Trading?
Kenneth A Lock's largest sale order was 2,368 units , worth over $37.8K on March 2, 2023. In total, Kenneth A Lock has made about 11 transactions over 3 years of their time at Arcutis Biotherapeutics, Inc. Kenneth A Lock usually trades in March, with the busiest year in 2020. The most recent transaction was a sale order of 831 units , worth over $12.68K on March 8, 2023.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Kenneth A Lock
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
InsideArbitrage
What is Kenneth A Lock's' Mailing Address?
- Mailing address is C/o Arcutis Biotherapeutics, Inc. 2945 Townsgate Road, Suite 110 Westlake Village CA 91361 CA
What are Arcutis Biotherapeutics, Inc's Past Insider Trades?
Arcutis Biotherapeutics, Inc's most recent insider trade came on August 22, 2023 by Patrick Burnett who sold 1,605 units worth $11.3K . In the last 3 years, insiders at Arcutis Biotherapeutics, Inc have sold an estimated value of $34.06M and bought an estimated value of $71.52M worth of shares. Insider trading is most common in March, with the busiest year in 2021. The most active traders at the company are Howard Welgus, Director, Todd Franklin Watanabe, See Remarks, and David W Osborne, Chief Technical Officer .
Arcutis Biotherapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |